Skip to main content
European Commission logo print header

The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use

Project description

Strategic pan-European approach to combat antimicrobial resistance

Antimicrobial resistance (AMR) causes numerous losses of lives worldwide. Antibiotic treatments need stratification to improve patient outcomes and limit the impact of AMR. The EU-funded VALUE-Dx project aims to develop policy and regulatory recommendations and understand value indicators and barriers for the adoption of community-acquired acute respiratory tract infections (CA-ARTI) diagnostics. The consortium of 6 in vitro diagnostic companies and 20 non-industry partners will define clinical algorithms and user requirements for CA-ARTI diagnostic tests. The value of diagnostics will be tested and demonstrated using pan-European clinical and laboratory research infrastructure, employing the innovative adaptive trial designs to evaluate novel CA-ARTI diagnostics.


Antimicrobial resistance (AMR) is of great public health concern, causing numerous losses of lives worldwide and threatening to reverse many of the considerable strides modern medicine has made over the last century. There is a need to stratify antibiotic and alternative treatments in terms of the actual benefit for the patient, improving patient outcome and limit the impact on AMR. High quality, effective and appropriate diagnostic tests to steer appropriate use of antibiotics are available. However, implementation of these tests into daily healthcare practice is hampered due to lack of insight in the medical, technological and health economical value and limited knowledge about psychosocial, ethical, regulatory and organisational barriers to their implementation into clinical practice.

VALUE-Dx will define and understand these value indicators and barriers to adoption of diagnostics of Community-Acquired Acute Respiratory Tract Infections (CA-ARTI) in order to develop and improve health economic models to generate insight in the whole value of diagnostics and develop policy and regulatory recommendations. In addition, efficient clinical algorithms and user requirement specifications of tests will be developed fuelling the medical and technological value of CA-ARTI diagnostics. The value of diagnostics will be tested and demonstrated in a unique pan-European clinical and laboratory research infrastructure allowing for innovative adaptive trial designs to evaluate novel CA-ARTI diagnostics. Close and continuous interaction with the VALUE-Dx multi-stakeholder platform provides for optimal alignment of VALUE-Dx activities with stakeholder opinions, expert knowledge and interests.

A variety of dissemination and advocacy measures will promote wide-spread adoption of clinical and cost-effective innovative diagnostics to achieve more personalized, evidence-based antibiotic prescription in order to transform clinical practice, improve patient outcomes and combat AMR.



Net EU contribution
€ 1 454 223,32
Prinsstraat 13
2000 Antwerpen

See on map

Vlaams Gewest Prov. Antwerpen Arr. Antwerpen
Activity type
Higher or Secondary Education Establishments
Other funding
€ 924 764,18

Participants (26)